Journal article
Development and validation of a sensitive LC-MS/MS method for the estimation of scopolamine in human serum
Journal of pharmaceutical and biomedical analysis, Vol.164, pp.41-46
02/05/2019
DOI: 10.1016/j.jpba.2018.09.051
PMID: 30396054
Abstract
Scopolamine is an anticholinergic alkaloid that is widely used in the form of a transdermal system to manage nausea associated with motion sickness. Currently available methods to quantify scopolamine require large sample volumes and involve cumbersome sample preparation. In this work, a simple method for the rapid separation and sensitive quantification of scopolamine in human serum was developed. Scopolamine was extracted from 0.5 mL of human serum using solid-phase extraction. The extracted samples were injected onto Zorbax XDB-Cl 8 column (4.6 x 50 mm, 1.8 mu m, and 600 bar) on an Agilent 1200 series HPLC. The chromatographic separation involved gradient elution with water and acetonitrile containing 0.1% v/v formic acid as a mobile phase. The samples were quantified in positive ion mode using a TSQ Quantum triple quadrupole mass spectrometer. The assay was validated and found to be linear over a concentration range of 5-5000 pg/mL. The total assay precision and accuracy was 6.3% and 96%, respectively. The lower limit of quantification (LLOQ) of the assay was 5 pg/mL. The assay was used in a human pharmacokinetic study to measure the concentration of scopolamine in serum after an administering scopolamine as transdermal delivery system or as an intravenous bolus dose. (C) 2018 Published by Elsevier B.V.
Details
- Title: Subtitle
- Development and validation of a sensitive LC-MS/MS method for the estimation of scopolamine in human serum
- Creators
- Suresh Kumar Swaminathan - University of MinnesotaJames Fisher - Analytical ServicesNicole K. Brogden - University of IowaKarunya K. Kandimalla - Pharmaceutics
- Resource Type
- Journal article
- Publication Details
- Journal of pharmaceutical and biomedical analysis, Vol.164, pp.41-46
- Publisher
- Elsevier
- DOI
- 10.1016/j.jpba.2018.09.051
- PMID
- 30396054
- ISSN
- 0731-7085
- eISSN
- 1873-264X
- Number of pages
- 6
- Grant note
- U.S. Food and Drug Administration (FDA) National Institute for Pharmaceutical Technology and Education (NIPTE) 5U01FD004275 / FDA; United States Department of Health & Human Services
- Language
- English
- Date published
- 02/05/2019
- Academic Unit
- Dermatology; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984296305202771
Metrics
11 Record Views